Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration
“We have treated mice with a new type of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression”
– Professor Andrew Tobin
An international team of scientists has announced a new advance in the fight against Alzheimer’s disease by identifying a new drug target for not only improving symptoms of brain degeneration – but also to extend the life-span of the terminally ill mice.
The four-year study by Medical Research Council (MRC) scientists based at the MRC Toxicology Unit at the University of Leicester is published in the Journal of Clinical Investigation. The study was led by Professor Andrew Tobin alongside colleagues from pharmaceutical company Eli Lilly and Company and the Monash Institute for Pharmaceutical Sciences in Australia. The project was also partly supported by the Wellcome Trust.
Corresponding author Professor Tobin, who alongside the lead researcher Dr Sophie Bradley has since moved from the University of Leicester to the University of Glasgow, said: “The paper describes drug-like molecules that can restore memory loss and slow progression of prion neurodegenerative disease in a manner that relates to the potential of these drugs in human Alzheimer’s disease.
“We have been using mice whose brain cells are progressively dying, similar to what happens in Alzheimer’s disease. This project focuses on a particular protein in the brain, which is proposed to be involved in Alzheimer’s disease, and as such could be a potential target for new drugs.
“We have treated mice with a new class of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice.”
The researchers state that drugs which activate this protein receptor in the brain have previously been tested in clinical trials for Alzheimer’s disease, and showed positive results with respect to improving cognition, but the patients experienced a large number of adverse side effects. This new class of drug is more selective and does not cause any side-effects when administered to mice in the study.
The study authors believe that this offers hope in the design of new drugs for improving cognition and extending life span.
Professor Tobin said: “This work may provide important information as to whether this protein is a viable drug target in the treatment of diseases associated with the progressive death of brain cells. This is of great importance to society, based on the fact that the treatment options for Alzheimer’s disease are very limited – there are no cures for Alzheimer’s disease and current treatments are focused on relieving some of the symptoms.
“What we have found is a novel class of drugs, called allosteric ligands, that target a protein called the M1 muscarinic receptor, which is present in the brain. Activating this receptor protein can not only improve cognitive function in mice with progressive brain degeneration, but when administered daily, can extend life span.”
The scientists say the work is important because it focuses on identifying a treatment that not only improves symptoms associated with neurodegeneration, like current treatments, but also identifies a new strategy for slowing disease progression and extending life-span.
Professor Tobin said: “Alzheimer’s disease is the most common form of dementia, and it affects an estimated 850,000 people in the UK alone. There are no treatments that can slow or halt the progression of Alzheimer’s, and patients are treated with drugs which temporarily mask the symptoms of the disease. Often these treatments are associated with side-effects which can limit patient compliance.
“I am proud to be involved in a collaboration with researchers across the world to address one of the world’s major healthcare challenges. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression.”
Receive an email update when we add a new ALZHEIMERS article.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Len Rome’s Local Health: Women and alzheimerson June 25, 2020 at 5:26 am
Two-thirds of alzheimers patients are females. They live longer than men, and living longer makes them more vulnerable.
- Alzheimers Q&A: What is Benson syndrome?on June 21, 2020 at 2:06 pm
Benson’s Syndrome, or posterior cortical atrophy, is a rare, progressive degenerative condition and is a form of dementia not considered a type of Alzheimer’s disease. Though PCA and ...
- 14th Star celebrates ‘longest day’ with Beer Garden for Alzheimer’s Awarenesson June 20, 2020 at 3:54 pm
On June 20th, people across the globe fought the darkness of Alzheimer’s Disease, through a fundraising activity of their choice, which would benefit the Alzheimers Association. On Saturday, ...
- Alzheimers Association Greater Michigan Chapter Preps for 2020 Summer Eventson June 17, 2020 at 10:18 am
The Alzheimers Association is prepping for its annual summer events. This year some of the festivities are going virtual, and this includes ‘The Longest Day’. ‘The Longest Day’ takes place during the ...
- Alzheimers Q&A: What is meant by the summer solstice or “The Longest Day” as referenced to Alzheimer’s disease?on June 14, 2020 at 2:00 pm
The summer solstice marks the first day of summer and arrives on June 20. In the northern hemisphere, the summer solstice marks the longest day of the year.
- State to help raise awareness, funds to fight Alzheimers on ‘Longest Day’on June 12, 2020 at 7:05 pm
On June 20 – the summer solstice and the day with the most light – Wisconsin residents will join advocates across the world to participate in “The Longest Day” to ...
- Could psychedelic drugs cure depression, alzheimers and chronic pain?on June 11, 2020 at 11:20 pm
In the 1950s and 1960s, psychedelic drugs (including LSD) showed real potential to treat psychiatric disorders and addictions, including alcoholism. Then the counter-culture embraced LSD for ...
- The Lost Generation: Living With Alzheimers And Dementia During The Coronaviruson June 9, 2020 at 9:24 am
Brianne remembers. But her mother does not. Brianne Grebil remembers a time before quarantine, when she would sit with her mom and hold her hand and pass the time thinking that, before mom had ...
- NCL moms and daughters deliver lunch to Alzheimers Coachella Valley familieson May 29, 2020 at 12:52 am
Teams of mothers and daughters from the National Charity League (NCL), Coachella Valley Chapter, delivered boxed lunches on Tuesday, May 12, to 21 Alzheimers Coachella Valley (ACV) families who ...
via Bing News